Biomaterials firm SINTX misses Q3 revenue estimates

SINTX Technologies

13/11/2025 13:09

Overview

SINTX Q3 revenue of $0.2 mln missed analyst expectations

Operating expenses decreased 51% yr/yr, reducing operating loss to $3.4 mln

Company strengthened liquidity with $4.3 mln raised through warrant exercises

Outlook

SINTX plans to launch the SINAPTIC wedge system in the near term

Company aims to expand clinical engagement in targeted surgical specialties

SINTX intends to leverage material science for polymer composites in implants

Result Drivers

FIRST PRODUCT REVENUE - Recorded initial revenue from OsseoSculpt, a private-labeled orthobiologic product

FACILITY OPTIMIZATION - Subleased Armor facility, saving up to $950,000 in lease costs

STRENGTHENED LIQUIDITY - Raised $4.3 mln through warrant inducement and exercises

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$200,000
$400,000 (1 Analyst)

Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for SINTX Technologies Inc is $25.00, about 86.3% above its November 12 closing price of $3.43

Press Release: ID:nGNX3fwCk3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)